摘要
现阶段心房颤动导管消融治疗的适应证应当从严掌握,主要基于以下理由:⑴心房颤动的机制还未完全明了;⑵该项治疗的有效性尚存疑问;⑶心房颤动导管消融治疗总体风险和复发率仍然偏高;⑷治疗技术难以推广普及;⑸我国心房颤动患者的药物治疗还有改善空间。
At present,the indication for catheter ablation of atrial fibrillation should be under strict control. The reasons are that the mechanisms of atrial fibrillation is still not clear,the therapeutic efficacy is yet to be established,the overall risk and recurrence rate remain high,it is difficult to popularize this technique and the pharmacotherapy of atrial fibrillation can be further improved in China.
出处
《心血管病学进展》
CAS
2006年第1期1-3,共3页
Advances in Cardiovascular Diseases
关键词
心房颤动
导管消融治疗
适应证
atrial fibrillation
catheter ablation
indication
